Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

BACKGROUND: Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date has comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Takayuki, Wakabayashi, Mako, Bhalla, Abhinav, Chopra, Nitin, Miyashita, Hirotaka, Mikami, Takahisa, Ueyama, Hiroki, Fujisaki, Tomohiro, Saigusa, Yusuke, Yamaji, Takahiro, Azushima, Kengo, Urate, Shingo, Suzuki, Toru, Abe, Eriko, Wakui, Hiromichi, Tamura, Kouichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792332/
https://www.ncbi.nlm.nih.gov/pubmed/33413348
http://dx.doi.org/10.1186/s12933-020-01197-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792332/
https://www.ncbi.nlm.nih.gov/pubmed/33413348
http://dx.doi.org/10.1186/s12933-020-01197-z

Ejemplares similares